The stock of Apricus Biosciences, Inc. (NASDAQ:APRI) is a huge mover today! The stock increased 13.50% or $0.3254 during the last trading session, reaching $2.7354. About 1.45 million shares traded or 401.91% up from the average. Apricus Biosciences, Inc. (NASDAQ:APRI) has declined 71.78% since January 14, 2017 and is downtrending. It has underperformed by 88.48% the S&P500.The move comes after 7 months positive chart setup for the $41.62 million company. It was reported on Jan, 14 by Barchart.com. We have $2.98 PT which if reached, will make NASDAQ:APRI worth $3.75M more.
COSMO PHARMACEUTICALS NV ORD NET (OTCMKTS:CMOPF) had an increase of 12.56% in short interest. CMOPF’s SI was 139,800 shares in January as released by FINRA. Its up 12.56% from 124,200 shares previously. It closed at $149 lastly. It is down 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, engages in developing therapies for gastrointestinal disorders and endoscopic procedures worldwide. The company has market cap of $. The company??s proprietary clinical development pipeline primarily addresses treatments for the gastro-intestinal tract, inflammatory bowel diseases , colon infections, and colon diagnosis. It currently has negative earnings. It markets Lialda/Mezavant/Mesavancol, an oral tablet formulation for the treatment of IBD; UCERIS/Cortiment, a glucocorticosteroid indicated for the induction of remission in active, mild to moderate Ulcerative Colitis; and Zacol NMX, a nutraceutical product that uses an amended form of the MMX technology in order to deliver butyric acid and inulin directly to the colon.
Analysts await Apricus Biosciences, Inc. (NASDAQ:APRI) to report earnings on March, 12. They expect $-0.13 earnings per share, down 225.00% or $0.09 from last year’s $-0.04 per share. After $-0.30 actual earnings per share reported by Apricus Biosciences, Inc. for the previous quarter, Wall Street now forecasts -56.67% EPS growth.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.